Important: The POPLINE website will retire on September 1, 2019. Click here to read about the transition.

Your search found 4 Results

  1. 1
    327143

    Missing the Target No. 5: Improving AIDS drug access and advancing health care for all.

    International Treatment Preparedness Coalition [ITPC]

    [Bangkok, Thailand], ITPC, 2007 Dec. [114] p.

    In the first section of the report, nine country teams provide first-hand reports on central issues related to AIDS service scale-up in their countries. Each demonstrates that increasing access to AIDS treatment brings not only better life and new hope, but also shines light on challenges and effective approaches to a spectrum of health, poverty, and human rights issues. In part two of this report, 14 national teams review drug access issues, and find that global and national processes for AIDS drug registration are burdened by inefficiencies, duplications, delay, and, in some instances, corruption. In many cases key ARVs, particularly newer and second-line therapies, are not yet registered in high impact countries - an administrative roadblock that puts lifesaving care out of reach for hundreds of thousands of people. The report makes a number of concrete recommendations to the key players who are responsible for making near universal access to AIDS treatment a reality by 2010. (excerpt)
    Add to my documents.
  2. 2
    322019

    Scaling up HIV / AIDS prevention, treatment and care: a report on WHO support to countries in implementing the “3 by 5” Initiative, 2004-2005.

    World Health Organization [WHO]. Treat 3 Million by 2005 Initiative

    Geneva, Switzerland, WHO, 2006. 143 p.

    In September 2003, LEE Jong-wook, Director-General of WHO, and Peter Piot, Executive Director of UNAIDS, declared the lack of access to antiretroviral therapy for HIV/AIDS in low- and middle-income countries to be a global health emergency. Shortly after this declaration, WHO and its partners launched a global initiative to scale up antiretroviral therapy with the objective of having 3 million people receiving antiretroviral therapy - representing half the total number of those globally in need - by the end of 2005 ("3 by 5"). Although the actual target of putting 3 million people on antiretroviral therapy was not reached by the end of 2005, countries have made significant progress in the past two years in expanding treatment coverage, strengthening prevention and building the capacity of health systems to deliver long-term, chronic care. Overall, in the two-year period, antiretroviral therapy coverage in low- and middle-income countries increased from 7% of those in need at the end of 2003 (400 000 people) to 20% of those in need at the end of 2005 (1.3 million people). Eighteen countries managed to increase antiretroviral therapy coverage to half or more of the people who needed it, consistent with the "3 by 5" target. (excerpt)
    Add to my documents.
  3. 3
    285603

    Sources and prices of selected medicines and diagnostics for people living with HIV / AIDS.

    UNICEF; Joint United Nations Programme on HIV / AIDS [UNAIDS]; World Health Organization [WHO]; Medecins Sans Frontières. Campaign for Access to Essential Medicines

    Geneva, Switzerland, WHO, 2004 Jun. [167] p. (WHO/EDM/PAR/2004.4; Development Experience Clearinghouse DocID / Order No. PN-ADB-693)

    Antiretroviral therapy, prevention and treatment of opportunistic infections and cancers, as well as palliative care are important elements of HIV/AIDS care and support. HIV/AIDS care hence requires a wide range of essential medicines. If available, these effective and often relatively inexpensive medicines can prevent, treat, or help manage HIV/AIDS and most of the common HIV-related diseases. Less than 8% of people who require antiretroviral (ARV) treatment can access these medicines in developing countries. The high price of many of the HIV-related medicines and diagnostics offered by common suppliers – especially antiretroviral and anti-cancer medicines – is one of the main barriers to their availability in developing countries. There are several other important barriers, including a lack of the basic components required for care, treatment, and support of people living with HIV/AIDS (PLWA) such as: trained staff in health facilities, constant availability of laboratory equipment and supplies, sufficient funding, efficient pharmaceutical services, strong political will and government commitment. Wider availability of information on prices and reliable sources of medicines can help those responsible for procurement make better decisions. Since 2000, prices of important first-line ARVs have fallen considerably. This trend is attributable to a cumulation of factors including advocacy, corporate responsiveness, competition from generic manufacturers, sustained public pressure, and the growing political attention paid to the AIDS epidemic. In addition, originator companies began announcing discount offers for the benefit of the poorest countries or those where HIV/AIDS prevalence is highest. (excerpt)
    Add to my documents.
  4. 4
    194660
    Peer Reviewed

    Achieving the WHO / UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost?

    Gutierrez JP; Johns B; Adam T; Bertozzi SM; Edejer TT

    Lancet. 2004 Jul 3; 364(9428):63-64.

    The “3 by 5” goal to have 3 million people in low and middle income countries on antiretroviral therapy (ART) by the end of 2005 is ambitious. Estimates of the necessary resources are needed to facilitate resource mobilisation and rapid channelling of funds to where they are required. We estimated the financial costs needed to implement treatment protocols, by use of country-specific estimates for 34 countries that account for 90% of the need for ART in resource-poor settings. We first estimated the number of people needing ART and supporting programmes for each country. We then estimated the cost per patient for each programme by country to derive total costs. We estimate that between US$5·1 billion and US$5·9 billion will be needed by the end of 2005 to provide ART, support programmes, and cover country-level administrative and logistic costs for 3 by 5. (author's)
    Add to my documents.